GSK Researchers Suppressed Data from China Tests of MS Drug
publication date: Jul 23, 2013
Two years ago, an internal audit of practices at GlaxoSmithKline’s Shanghai R&D facility showed serious problems. Researchers did not report a total of six test results of a multiple sclerosis drug. By the time the tests were discovered, the drug, ozanezumab, was already being tested in humans. When GSK officials looked at the data, they stopped testing the drug in patients with MS, though trials for Lou Gherig’s disease were allowed to continue. The New York Times
obtained a copy of the audit and broke the story, which was not previously known. More details....
Stock Symbol: (NYSE: GSK)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.